The VITA project: Phenotypic resistance to activated protein C and FV Leiden mutation in the general population

Thrombosis and Haemostasis

Volumn 78, Issue 2, 1997, Pages 859-863

  Tosetto, Alberto ^a   Missiaglia, Edoardo ^a   Gatto, Elisabetta ^a   Rodeghiero, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; CHOLESTEROL; FIBRINOGEN; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

AGE; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD GROUP; BODY MASS; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DIAGNOSTIC VALUE; DISEASE RESISTANCE; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; GENE MUTATION; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PRIORITY JOURNAL; RISK; SCREENING; SMOKING HABIT; TRIACYLGLYCEROL BLOOD LEVEL; VEIN THROMBOSIS;

EID: 0030757480     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657642     Document Type: Article

References (45)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
2. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
3. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
4. Svensson PJ, Dahlbäck B. Twenty novel families with thrombophilia and inherited resistance to activated protein C. Thromb Haemost 1993; 69: 1252.
5. Svensson PJ, Dahlbäck B. Novel mechanism for thrombosis characterised by poor anticoagulant response to activated protein C constitutes a major cause of thrombophilia. Thromb Haemost 1993; 69: 999.
6. Tosetto A, Gatto E, Masiero MT, Rodeghiero F. APC-Resistance in the general population. Relationship with other coagulation variables and with venous thrombotic history. Br J Haematol 1994; 87 (Suppl 1): 188.
7. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
8. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
9. Rees DC. The population genetics of Factor V Leiden (Arg506Gln). Br J Haematol 1996; 95: 579-86.
10. Dahlbäck B. Resistance to activated protein C, the Arg506 to Gln mutation in the Factor V gene, and venous thrombosis. Functional tests and DNA-based assay, pros and cons. Thromb Haemost 1995; 73: 739-42.
11. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
12. Vasse M, Gaucher C, Beufe S, Van Dreden P, Monconduit M, Mazurier C. Analysis of Factor VIII in a family with inherited resistance to activated protein C without factor V Leiden. Thromb Haemost 1995; 73: 1369.
13. Faioni EM, Franchi F, Asti D, Mannucci PM. Aquired resistance to activated protein C develops during pregnancy. Thromb Haemost 1995; 73: 1373.
14. Ehrenforth S, Radtke KP, Zwinge B, Siegert S, Scharrer I. Acquired APC-resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 73: 1368.
15. Rodeghiero F, Tosetto A. Some remarks on the epidemiology of thrombotic disorders. Thromb Haemost 1993; 69: 527-8.
16. Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. Boston: PWS-Kent Publishing Company, 1988.
17. Rodeghiero F, Tosetto A. The VITA Project: Population-based distribution of Protein C, Antithrombin III, Heparin Cofactor II and plasminogen. Relationship with physiological variables and establishment of reference ranges. Thromb Haemost 1996; 76: 226-33.
18. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996; 143: 1257-65.
19. Adell K, Ogbonna G. Rapid purification of human DNA from whole blood for potential application in clinical chemistry laboratories. Clin Chem 1990; 36: 261-4.
20. Siedel J, Hagele EO, Ziegerhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-80.
21. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379-88.
22. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-80.
23. Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995; 73: 732-3.
24. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons 1989.
25. Galen RS, Gambino SR. The predictive value and efficiency of medical diagnoses. New York: John Wiley & Sons 1975.
26. Daniel WW. Biostatistics: a foundation for analysis in the health sciences. New York: J. Wiley & Sons 1987.
27. Tosetto A, Gatto E, Masiero MT, Rodeghiero F. Parallel line bioassay or single-point calibration for the establishment of reference ranges. Thromb Res 1994; 75: 479-83.
28. Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem 1971; 17: 275-84.
29. StataCorp. Stata Statistical Software 1995.
30. Cadroy Y, Sié P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994; 83: 2008-9.
31. Henkens CM, van der Meer J, van der Schaaf W, Pelsma PM, Geerards S, Seinen A, Bom VJ. Sensitivity to activated protein C (APC) related with sex, use of oral contraceptives and FVIII. Thromb Haemost 1995; 73: 1120.
32. Olivieri O, Friso S, Manzato F, Guella A, Bernardi F, Longhi B, Girelli D, Azzini M, Brocco G, Russo C, Corrocher R. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-70.
33. de Ronde H, Bertina RM. Laboratory diagnosis of APC-Resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
34. Lindberg UB, Crona N, Stigendal L. Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost 1989; 61: 65-9.
35. Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Della Volpe A, Zanussi C. Short-and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugate equine estrogens, combined with medroxy-progesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res 1991; 62: 1-8.
36. Vasse M, Leduc O, Borg J, Chretien MH, Monconduit M. Resistance to activated protein C: evaluation of three functional assays. Thromb Res 1994; 76: 47-59.
37. Rao AK, Elliott D, Stadnicki A, DeLa Cadena R. High levels of plasma FVIIIC impair anticoagulant response to activated protein C. Thromb Haemost 1995; 73: 1126.
38. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
39. Solberg HE. Approved recommendation (1987) on the theory of reference values. Part 5. Determination of reference limits. J Clin Chem Clin Biochem 1987; 25: 645-56.
40. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-3.
41. Trossaert M, Conard J, Horellou HM, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709.
42. Svensson PJ, Zoller B. Dahlbäck B. Evaluation of original and modified APC-resistance test in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-5.
43. Trossaert M, Conard J, Horellou HM, Elalamy I, Samama MM. The modified APC resistance test in the presence of Factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996; 75: 521-2.
44. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995; 345: 152-5.
45. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCV. Hemostatic risk factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.